Vergoeding 2017-2021 voor ATC-subgroep A10B : Bloedglucoseverlagende middelen excl. insulines
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| A10BA Biguaniden | 8.526.600 | 8.700.100 | 9.077.400 | 10.345.300 | 12.029.400 |
| A10BB Sulfonylureumderivaten | 6.534.800 | 7.491.900 | 8.659.900 | 8.908.100 | 10.596.000 |
| A10BD Combinaties van bloedglucoseverlagende middelen | 3.684.500 | 3.648.000 | 3.622.000 | 3.630.200 | 3.511.800 |
| A10BF Alfa-glucosidaseremmers | 132.840 | 138.420 | 125.090 | 109.740 | 94.877 |
| A10BG Thiazolidinedionen | 163.250 | 112.350 | 81.449 | 60.943 | 83.198 |
| A10BH Dipeptidylpeptidase-4-remmers | 11.946.600 | 12.410.000 | 14.413.100 | 15.605.600 | 15.166.800 |
| A10BJ Glucagonachtig peptide-1-agonisten (glp-1-agonisten) | 14.923.600 | 17.773.200 | 26.528.700 | 40.026.600 | 50.246.600 |
| A10BK Natriumglucose-cotransporter-2-remmers (sglt-2-remmers) | 3.669.500 | 5.536.000 | 6.186.500 | 7.379.600 | 10.155.700 |
| A10BX Overige bloedglucoseverlagende middelen excl. insulines | 39.349 | 42.598 | 51.374 | 55.573 | 50.930 |
| Totaal | 49.621.039 | 55.852.568 | 68.745.513 | 86.121.656 | 101.935.305 |